NFL BIOSCIENCES : SETTING UP A LIQUIDITY CONTRACT
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has implemented a liquidity contract with INVEST SECURITIES as of Monday July 19 2021.
This liquidity contract was drawn up in accordance with the provisions provided for by the legal framework in force since November 2018, and more particularly by the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on abuses. market (MAR), of Commission Delegated Regulation (EU) 2016/908 of February 26, 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regulatory technical standards on criteria, procedure and the requirements concerning the establishment of an accepted market practice and the requirements linked to its maintenance, its abolition or the modification of its conditions of admission, of articles L. 225-209 and following of the Commercial Code and AMF decision No. 2018-01 of July 2, 2018 establishing liquidity contracts on equity securities under accepted market practice and all other provisions referred to therein.
It was concluded for an initial period of 2 years renewable by tacit agreement for successive periods of one year.
For the implementation of the contract, the following means appear on July 19, 2021 on the NFL BIOSCIENCES liquidity account:
- € 99,999.32 in cash
- 30,993 titles
The execution of the liquidity contract will be suspended under the conditions referred to in Article 5 of AMF Decision No. 2018-01 of July 2, 2018.
About NFL Biosciences
NFL Biosciences is a Montpellier-based biopharmaceutical company whose most advanced botanical drug candidate is a smoking cessation aid. Called NFL-101, this natural product, extracted from standardized tobacco leaves and devoid of nicotine, is protected by two families of patents. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, long-term effective, short and personalized alternative.
Beyond NFL-101, NFL Biosciences has plans to develop botanical drugs for the treatment of cannabis use disorders and alcoholism.
More information on www.nflbiosciences.com
Bruno Lafont – email@example.com – 04 11 93 76 67
Calyptus Agency – firstname.lastname@example.org – 01 53 65 68 68